Status:
COMPLETED
A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura
Lead Sponsor:
Bloodworks
Collaborating Sponsors:
University of Washington
Conditions:
Purpura, Thrombotic Thrombocytopenic
TTP
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
In this study, the investigators want to determine if N-acetylcysteine(NAC), given intravenously, will decrease complications in patients with Thrombotic Thrombocytopenia Purpura (TTP) who are receivi...
Detailed Description
Thrombotic thrombocytopenic purpura (TTP) is a rare hemostatic disorder with life threatening consequences secondary to microvascular thrombosis. While the use of therapeutic plasma exchange (TPE) has...
Eligibility Criteria
Inclusion
- Age \>= 18 years of age
- Diagnosis of suspected TTP (lab evidence of hemolysis, platelet count \<120,000, schistocytes on peripheral smear)
- Plans for or just initiated therapeutic plasma exchange (TPE), and before 3rd TPE
- Normal baseline prothrombin time (PT) and activated partial thromboplastin time (aPTT)
- Anticipated TPE for \> 5 days
Exclusion
- Asthma
- Life expectancy \< 1 week
- Liver function tests abnormal- (ALT, direct bilirubin \> three times upper normal limit)
- Known underlying bleeding disorder
- Pregnancy or nursing
- Known allergy to NAC
- Phosphodiesterase Type 5 inhibitors, nitroglycerin, or carbamazepine current use
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2017
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT01808521
Start Date
May 1 2013
End Date
July 1 2017
Last Update
September 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Puget Sound Blood Center
Seattle, Washington, United States, 98104